We are live on ! Find out more
LMR Partners

LMR Partners Portfolio holdings

AUM $32.6B Turnover 45.82%
1-Year Est. Return 45.61%
 

LMR Partners is a British multi-strategy investment firm named after its three founders, Ben Levine, Andrew Manuel and Stefan Renold, whose surname initials spell LMR. All three had been traders at UBS and Goldman Sachs, and Paloma Partners provided seed money before the firm began trading in 2010. Manuel left in 2015 and launched Ixworth Capital, his own global macro hedge fund. The firm focuses on global macro and event-driven strategies, mixing computer-model trading with trades chosen by its portfolio managers.

This Fund
S&P 500
This Quarter Est. Return
+4.46%
1 Year Est. Return
+45.61%
3 Year Est. Return
+238.3%
5 Year Est. Return
+283.63%
10 Year Est. Return
+733.38%
AUM
$32.6B
AUM Growth
+$5.8B
Cap. Flow
-$2.24B
Cap. Flow %
-6.88%
Top 10 Hldgs %
23.21%
Holding
1,999
New
513
Increased
354
Reduced
302
Closed
403
Avg Time Held Equity + Options
0.7 years
Top 10 Avg Time Held Equity + Options
0.2 years
Top 20 Avg Time Held Equity + Options
0.4 years
Avg Time Held Equity only
0.7 years
Top 10 Avg Time Held Equity only
0.5 years
Top 20 Avg Time Held Equity only
0.6 years

Top Buys

Rank Stock Value
1
LNTH icon
Lantheus
LNTH
+$215M
2
NVS icon
Novartis
NVS
+$116M
3
LITE icon
Lumentum
LITE
+$91.8M
4
MDT icon
Medtronic
MDT
+$90.8M
5
SHOP icon
Shopify
SHOP
+$88.5M

Sector Composition

Rank Sector Weight
1 Miscellaneous 74.57%
2 Technology 7.25%
3 Healthcare 5.19%
4 Communication Services 3.16%
5 Financials 2.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
FANG icon
1026
Diamondback Energy
FANG
$48.7B
$1.18M ﹤0.01%
+6,423
New +$1.26M
2026 Q3
0 quarters
ROP icon
1027
Roper Technologies
ROP
$46.6B
$1.16M ﹤0.01%
+3,311
New +$1.27M
2026 Q3
0 quarters
CSGP icon
1028
CoStar Group
CSGP
$12B
$1.15M ﹤0.01%
+41,979
New +$1.26M
2026 Q3
0 quarters
LH icon
1029
Labcorp
LH
$30.1B
$1.14M ﹤0.01%
3,689
+2,931
+387% +$909K
2026 Q2
1 quarter
GENVR icon
1030
Gen Digital Contingent Value Rights
GENVR
$1.13M ﹤0.01%
1,308,456
+542,569
+71% +$1.54M
2025 Q2
5 quarters
PYXS icon
1031
Pyxis Oncology
PYXS
$169M
$1.12M ﹤0.01%
+482,750
New +$1.46M
2026 Q3
0 quarters
CNH icon
1032
CNH Industrial
CNH
$18B
$1.12M ﹤0.01%
+86,847
New +$1.01M
2026 Q3
0 quarters
ADP icon
1033
Automatic Data Processing
ADP
$121B
$1.11M ﹤0.01%
4,304
-1,315
-23% -$349K
2026 Q1
2 quarters
GSHD icon
1034
Goosehead Insurance
GSHD
$1.11B
$1.11M ﹤0.01%
+24,462
New +$1.46M
2026 Q3
0 quarters
CAPR icon
1035
CALL
Capricor Therapeutics
CAPR
$467M
$1.11M ﹤0.01%
117,100
– –
2025 Q1
6 quarters
KDKRW icon
1036
Kodiak AI Warrants
KDKRW
$1.1M ﹤0.01%
3,544,339
+709
+0% +$465
2025 Q1
6 quarters
TDACW icon
1037
Translational Development Acquisition Corp Warrants
TDACW
$6.04M
$1.09M ﹤0.01%
755,000
– –
2025 Q1
6 quarters
NEOG icon
1038
Neogen
NEOG
$2.42B
$1.08M ﹤0.01%
+84,530
New +$959K
2026 Q3
0 quarters
MVLL icon
1039
PUT
GraniteShares 2x Long MRVL Daily ETF
MVLL
$109M
$1.08M ﹤0.01%
30,100
+100
+0.3% +$2.85K
2026 Q2
1 quarter
TRVI icon
1040
Trevi Therapeutics
TRVI
$1.93B
$1.07M ﹤0.01%
75,000
-25,000
-25% -$430K
2025 Q1
6 quarters
TEM icon
1041
Tempus AI
TEM
$11.6B
$1.07M ﹤0.01%
+13,094
New +$790K
2026 Q3
0 quarters
EWL icon
1042
iShares MSCI Switzerland ETF
EWL
$2.97B
$1.07M ﹤0.01%
+18,100
New +$1.13M
2026 Q3
0 quarters
BKNG icon
1043
Booking.com
BKNG
$114B
$1.06M ﹤0.01%
6,492
-1,748
-21% -$329K
2025 Q4
3 quarters
CDNS icon
1044
PUT
Cadence Design Systems
CDNS
$83.9B
$1.06M ﹤0.01%
+3,200
New +$1.05M
2026 Q3
0 quarters
CTAS icon
1045
Cintas
CTAS
$88.2B
$1.05M ﹤0.01%
5,406
-26,984
-83% -$5.37M
2026 Q1
2 quarters
PSQLW icon
1046
Pasqal Holding Warrant
PSQLW
$1.05M ﹤0.01%
+980,179
New +$1.46M
2026 Q3
0 quarters
NGEN icon
1047
NervGen Pharma
NGEN
$204M
$1.05M ﹤0.01%
550,000
-50,000
-8% -$95.8K
2026 Q2
1 quarter
CHPGU icon
1048
ChampionsGate Acquisition Corp Unit
CHPGU
$72.5M
$1.05M ﹤0.01%
100,000
– –
2025 Q2
5 quarters
MTAL.U icon
1049
Metals Acquisition Corp II Units
MTAL.U
$1.05M ﹤0.01%
100,000
– –
2026 Q1
2 quarters
LLY icon
1050
CALL
Eli Lilly
LLY
$1.23T
$1.04M ﹤0.01%
+900
New +$1.06M
2026 Q3
0 quarters

Similar funds

LMR Partners's Q3 2026 Portfolio in Review

As of Q3 2026, LMR Partners held 1,999 positions worth $32.6B, up 22% from $26.8B the previous quarter. Its ten largest holdings account for 23% of the portfolio.

LMR Partners withdrew a net $2.24B in Q3 2026, closing 403 positions and reducing 302 holdings. Its most notable exit was Chart Industries, an estimated $109M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 75% of assets, up from 71% a quarter earlier, followed by Technology and Healthcare.

Against the trend, LMR Partners opened a new position in Lantheus worth $210M.

  • LMR Partners's largest Q3 2026 buy was Lantheus: 2,108,000 shares worth $210M.
  • LMR Partners added most to Novartis in Q3 2026, an estimated $116M increase.
  • LMR Partners's biggest Q3 2026 reduction was iShares Core S&P 500 ETF, cutting an estimated $632M.
  • LMR Partners fully exited Chart Industries in Q3 2026, selling an estimated $109M.
  • LMR Partners's ten largest holdings make up 23% of its $32.6B portfolio in Q3 2026.
  • LMR Partners opened 513 new positions and closed 403 in Q3 2026.
  • LMR Partners's portfolio value rose 22% quarter-over-quarter to $32.6B.

Based on LMR Partners's 13F filing for Q3 2026, filed 16 Nov 2026.